公开(公告)号：US20240316161A1

公开(公告)日：2024-09-26

申请号：US18482248

申请日：2023-10-06

Applicant: Bristol-Myers Squibb Company

Inventor： Sharon CLOAD ,  Linda ENGLE ,  Dasa LIPOVSEK ,  Malavi MADIREDDI ,  Ginger Chao RAKESTRAW ,  Joanna SWAIN ,  Wenjun ZHAO ,  Hui WEI ,  Aaron P. YAMNIUK ,  Vidhyashankar RAMAMURTHY ,  Alexander T. KOZHICH ,  Martin J. CORBETT ,  Stanley Richard KRYSTEK, JR.

IPC: A61K38/39 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/60 ,  A61K47/64 ,  C07K14/435 ,  C07K14/765 ,  C07K14/78 ,  C07K14/79 ,  C07K16/18 ,  C07K16/46 ,  G01N33/74

CPC classification number: A61K38/39 ,  A61K38/17 ,  A61K38/1709 ,  A61K45/06 ,  A61K47/60 ,  A61K47/642 ,  C07K14/435 ,  C07K14/765 ,  C07K14/78 ,  C07K14/79 ,  C07K16/18 ,  C07K16/46 ,  G01N33/74 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/31

Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.

公开(公告)号：US20240277812A1

公开(公告)日：2024-08-22

申请号：US18645005

申请日：2024-04-24

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： Patricia K. DONAHOE ,  David PEPIN

IPC: A61K38/22 ,  A61K9/00 ,  A61K38/17 ,  A61P15/08 ,  A61P15/18 ,  C12N7/00

CPC classification number: A61K38/22 ,  A61K9/0019 ,  A61K38/17 ,  A61P15/08 ,  A61P15/18 ,  C12N7/00 ,  C12N2750/14142 ,  C12N2750/14171

Abstract: One aspect of the invention provides a method of contraception by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). The MIS can be produced endogenously in the subject by a vector, where the vector comprises a polynucletide encoding a recombinant MIS protein. In some embodiments, the contraception is permanent and only requires administration of the composition once. Another aspect of the invention relates to a method of preserving an ovarian reserve, the method comprising administering to a female subject a composition comprising MIS or an inducible vector that comprises a polynucleotide encoding a recombinant MIS protein.

公开(公告)号：US20240247047A1

公开(公告)日：2024-07-25

申请号：US18442988

申请日：2024-02-15

Applicant: Sanford Burnham Prebys Medical Discovery Institute ,  PFIZER INC.

Inventor： Carl F. Ware ,  John Sedy ,  Tigran Aivazian ,  Brian Miller ,  Natasha K. Crellin

IPC: C07K14/71 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/68 ,  C07K14/705 ,  C07K14/715 ,  C07K19/00

CPC classification number: C07K14/71 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1793 ,  A61K45/06 ,  A61K47/68 ,  C07K14/70578 ,  C07K14/70596 ,  C07K14/715 ,  C07K19/00 ,  A61K38/00 ,  C07K2319/30

Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

公开(公告)号：US20240226330A9

公开(公告)日：2024-07-11

申请号：US18143902

申请日：2023-05-05

Applicant: Eli Lilly and Company

Inventor： Steven Pennock ,  Adrian M. Timmers ,  Mark Shearman ,  Christopher Bartolome ,  Wang Xiaobo ,  Prahav Dinesh Mathur ,  Phillip M. Uribe ,  Stephanie Szobota ,  Bonnie E. Jacques ,  Alan C. Foster ,  Fabrice Piu

IPC: A61K48/00 ,  A61K38/17 ,  A61P27/16

CPC classification number: A61K48/0058 ,  A61K38/17 ,  A61K48/0066 ,  A61P27/16

Abstract: Described herein are variant adeno-associated virus (AAV) capsid polypeptides and gene therapeutics thereof for use in the treatment or prevention of hearing loss.

公开(公告)号：US20240216467A1

公开(公告)日：2024-07-04

申请号：US18449039

申请日：2023-08-14

Applicant: CSL Limited

Inventor： Craig RAYNER

IPC: A61K38/17 ,  A61K35/14 ,  A61K45/06

CPC classification number: A61K38/1709 ,  A61K35/14 ,  A61K38/17 ,  A61K45/06

Abstract: An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to cardiovascular disease, acute coronary syndrome, atherosclerosis, unstable angina pectoris, and myocardial infarction. More particularly, the fixed dosage apolipoprotein formulation displays relatively reduced inter-patient variability compared to weight-adjusted dosages. Typically, the apolipoprotein formulation is a reconstituted high density lipoprotein formulation comprising ApoA1, one or more lipids such as phosphatidylcholine, sphingomyelin and/or phosphatidylglycerol and, optionally, a detergent such as cholate at a level that does not induce liver toxicity.

公开(公告)号：US12011463B2

公开(公告)日：2024-06-18

申请号：US16933492

申请日：2020-07-20

Applicant: Reapplix ApS

Inventor： Rasmus Lundquist ,  Niels Erik Holm

IPC: A61K35/19 ,  A61K35/15 ,  A61K35/33 ,  A61K38/15 ,  A61K38/17 ,  A61K38/36 ,  A61L24/10 ,  B04B5/04 ,  C12N5/078 ,  C12N5/0787 ,  G01N33/49 ,  A61L26/00 ,  A61M1/02

CPC classification number: A61K35/19 ,  A61K35/15 ,  A61K35/33 ,  A61K38/15 ,  A61K38/17 ,  A61K38/36 ,  A61K38/363 ,  A61L24/106 ,  B04B5/04 ,  C12N5/0642 ,  C12N5/0644 ,  G01N33/49 ,  A61L26/0042 ,  A61M1/029 ,  B04B2005/0485 ,  C12N2501/905 ,  G01N33/491 ,  A61K38/363 ,  A61K2300/00 ,  A61K38/15 ,  A61K2300/00 ,  A61K38/17 ,  A61K2300/00 ,  A61K35/19 ,  A61K2300/00 ,  A61K35/15 ,  A61K2300/00

Abstract: A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

公开(公告)号：US11998590B2

公开(公告)日：2024-06-04

申请号：US16988248

申请日：2020-08-07

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： Patricia K. Donahoe ,  David Pepin

IPC: A61K38/22 ,  A61K9/00 ,  A61K38/17 ,  A61P15/08 ,  A61P15/18 ,  C12N7/00

CPC classification number: A61K38/22 ,  A61K9/0019 ,  A61K38/17 ,  A61P15/08 ,  A61P15/18 ,  C12N7/00 ,  C12N2750/14142 ,  C12N2750/14171

Abstract: One aspect of the invention provides a method of contraception by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). The MIS can be produced endogenously in the subject by a vector, where the vector comprises a polynucletide encoding a recombinant MIS protein. In some embodiments, the contraception is permanent and only requires administration of the composition once. Another aspect of the invention relates to a method of preserving an ovarian reserve, the method comprising administering to a female subject a composition comprising MIS or an inducible vector that comprises a polynucleotide encoding a recombinant MIS protein.

公开(公告)号：US20240165140A1

公开(公告)日：2024-05-23

申请号：US18512519

申请日：2023-11-17

Applicant: TSINGHUA UNIVERSITY ,  BEIJING PROTGEN LTD.

Inventor： Yongzhang LUO ,  Lin JIA ,  Guodong CHANG

IPC: A61K31/7048 ,  A61K38/17 ,  A61P35/00

CPC classification number: A61K31/7048 ,  A61K38/17 ,  A61P35/00

Abstract: A method for treating a tumor or cancer by means of a treatment scheme of using endostatin in combination with induction of DNA double-strand breaks, and a medication. The method and composition are used for treating a tumor or cancer related to loss of p53 function, or a tumor or cancer occurring when p53 function is normal.

公开(公告)号：US20240141367A1

公开(公告)日：2024-05-02

申请号：US18405964

申请日：2024-01-05

Applicant: The Regents of the University of California

Inventor： Steve E. JACOBSEN ,  Javier GALLEGO-BARTOLOMÉ ,  Ashot PAPIKIAN ,  Jason GARDINER

IPC: C12N15/82 ,  A61K38/17 ,  C12N15/86

CPC classification number: C12N15/8213 ,  A61K38/17 ,  C12N15/8216 ,  C12N15/86

Abstract: The present disclosure relates to the use of recombinant proteins for inducing epigenetic modifications at specific loci, as well as to methods of using these recombinant proteins for modulating the expression of genes in plants.

公开(公告)号：US11883461B2

公开(公告)日：2024-01-30

申请号：US17898994

申请日：2022-08-30

Applicant: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH

Inventor： Yousef Al-Abed

IPC: A61K38/17 ,  A61K9/00 ,  C07K1/113 ,  A61P25/02 ,  A61K47/65 ,  C07K14/47 ,  A61K31/197 ,  A61K47/10 ,  A61K47/26 ,  A61K38/07 ,  C07K5/107 ,  A61K38/00 ,  A61K9/08

CPC classification number: A61K38/17 ,  A61K9/007 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/197 ,  A61K38/07 ,  A61K47/10 ,  A61K47/26 ,  A61K47/65 ,  A61P25/02 ,  C07K1/113 ,  C07K5/1016 ,  C07K14/4703 ,  A61K9/08 ,  A61K38/00

Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.